IFS Advisors LLC Purchases 3,277 Shares of Pfizer Inc. (NYSE:PFE)

IFS Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 787.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,693 shares of the biopharmaceutical company’s stock after acquiring an additional 3,277 shares during the period. Pfizer comprises about 0.1% of IFS Advisors LLC’s portfolio, making the stock its 23rd largest position. IFS Advisors LLC’s holdings in Pfizer were worth $98,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Winch Advisory Services LLC grew its stake in Pfizer by 6.5% in the fourth quarter. Winch Advisory Services LLC now owns 17,265 shares of the biopharmaceutical company’s stock valued at $458,000 after purchasing an additional 1,053 shares during the last quarter. Roble Belko & Company Inc grew its position in shares of Pfizer by 49.7% in the 4th quarter. Roble Belko & Company Inc now owns 5,801 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 1,926 shares during the last quarter. Advisors Management Group Inc. ADV raised its stake in shares of Pfizer by 1.4% during the 4th quarter. Advisors Management Group Inc. ADV now owns 192,185 shares of the biopharmaceutical company’s stock worth $5,099,000 after acquiring an additional 2,706 shares in the last quarter. ARS Wealth Advisors Group LLC lifted its position in Pfizer by 4.9% during the fourth quarter. ARS Wealth Advisors Group LLC now owns 24,967 shares of the biopharmaceutical company’s stock valued at $662,000 after acquiring an additional 1,176 shares during the last quarter. Finally, Burney Co. boosted its stake in Pfizer by 262.8% in the fourth quarter. Burney Co. now owns 143,731 shares of the biopharmaceutical company’s stock valued at $3,813,000 after acquiring an additional 104,112 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Buying and Selling at Pfizer

In related news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on PFE shares. Citigroup assumed coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Wolfe Research began coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Stock Down 0.4 %

PFE stock opened at $26.12 on Thursday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm’s fifty day moving average is $26.13 and its 200 day moving average is $28.03. The firm has a market cap of $148.02 billion, a PE ratio of 35.30, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) EPS. On average, research analysts forecast that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.58%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.